The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Overview of attention for article published in Journal of Translational Medicine, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 4 X users
patent: 2 patents

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 95 Dimensions

Readers on

mendeley: 114 Mendeley

Summary X Patents Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 1 public wall post.

Stojdl Lab, 15 Nov 2019

An 18-gene tumour inflammation signature (TIS) panel can predict the clinical benefit of anti-PD-1 #immune checkpoint blockade.

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.